Lane Morgan
Investor Relations, Pomonix
Replay available
Pulmonx Corporation (NASDAQ: LUNG) Q1 2025 earnings conference call, held 2025-04-30. Replay captured from the company's public earnings webcast.

Investor Relations, Pomonix
President and Chief Executive Officer, Pomonix
Chief Financial Officer, Pomonix
Analyst, Lake Street Capital Markets
Unspecified
Analyst, Canaccord
Analyst, Piper Sandler
Ladies and gentlemen, thank you for standing by and welcome to Palman Next First Quarter 2025 Earnings Conference Call. At this time, all participants are on the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Lane Morgan, Investor Relations. Please go ahead. Good afternoon, and thank you for participating in today's call. Joining me from Pomonix are Steve Williamson, President and Chief Executive Officer, and Mehul Joshi, Chief Financial Officer. Earlier today, Pomonix issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is available on Pomonix's website. Before we begin, I'd like to remind you that management will make statements during the call that include forward-looking statements within the meeting of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our operating trends, commercial strategies, and future financial performance, the timing and results of clinical trials, physician engagement, expense management, market opportunity, guidance for revenue, gross margin, and operating expenses. Commercial expansion and...